Name | Number of supported studies | Average coverage | |
---|---|---|---|
glutamatergic neuron | 7 studies | 32% ± 10% | |
neuron | 6 studies | 40% ± 18% | |
mesothelial cell | 5 studies | 48% ± 18% | |
GABAergic neuron | 5 studies | 27% ± 10% | |
oligodendrocyte precursor cell | 4 studies | 28% ± 12% | |
interneuron | 3 studies | 32% ± 16% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 3 studies | 24% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 80% | 5707.94 | 2108 / 2642 | 99% | 52.87 | 699 / 705 |
intestine | 53% | 507.94 | 516 / 966 | 26% | 0.90 | 137 / 527 |
pancreas | 0% | 0 | 0 / 328 | 79% | 11.15 | 140 / 178 |
stomach | 43% | 277.27 | 154 / 359 | 26% | 0.74 | 74 / 286 |
lymph node | 0% | 0 | 0 / 0 | 55% | 2.62 | 16 / 29 |
ovary | 2% | 9.84 | 4 / 180 | 47% | 4.69 | 201 / 430 |
breast | 1% | 2.88 | 3 / 459 | 45% | 1.32 | 504 / 1118 |
kidney | 0% | 0 | 0 / 89 | 43% | 2.52 | 390 / 901 |
adrenal gland | 1% | 4.29 | 2 / 258 | 40% | 5.12 | 92 / 230 |
lung | 2% | 13.86 | 14 / 578 | 36% | 1.19 | 415 / 1155 |
uterus | 9% | 79.32 | 15 / 170 | 25% | 3.88 | 115 / 459 |
esophagus | 21% | 132.88 | 305 / 1445 | 13% | 2.00 | 23 / 183 |
liver | 0% | 0 | 0 / 226 | 28% | 0.87 | 114 / 406 |
bladder | 0% | 0 | 0 / 21 | 27% | 1.83 | 136 / 504 |
prostate | 1% | 4.14 | 2 / 245 | 22% | 1.04 | 112 / 502 |
thymus | 0% | 1.40 | 2 / 653 | 20% | 0.86 | 119 / 605 |
skin | 0% | 1.30 | 4 / 1809 | 18% | 0.74 | 86 / 472 |
eye | 0% | 0 | 0 / 0 | 15% | 0.34 | 12 / 80 |
tonsil | 0% | 0 | 0 / 0 | 11% | 0.16 | 5 / 45 |
adipose | 2% | 11.15 | 24 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 1% | 8.65 | 16 / 1335 | 0% | 0 | 0 / 0 |
heart | 0% | 1.38 | 3 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
muscle | 0% | 0 | 0 / 803 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spleen | 0% | 0 | 0 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0095500 | Biological process | acetylcholine receptor signaling pathway |
GO_0007399 | Biological process | nervous system development |
GO_0009887 | Biological process | animal organ morphogenesis |
GO_0098552 | Cellular component | side of membrane |
GO_0045202 | Cellular component | synapse |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0033130 | Molecular function | acetylcholine receptor binding |
GO_0005515 | Molecular function | protein binding |
GO_0030550 | Molecular function | acetylcholine receptor inhibitor activity |
Gene name | LY6H |
Protein name | Lymphocyte antigen 6H (Ly-6H) |
Synonyms | |
Description | FUNCTION: Believed to act as a modulator of nicotinic acetylcholine receptors (nAChRs) activity. In vitro inhibits alpha-3:beta-4-containing nAChRs maximum response. May play a role in the intracellular trafficking of alpha-7-containing nAChRs and may inhibit their expression at the cell surface. Seems to inhibit alpha-7/CHRNA7 signaling in hippocampal neurons. . |
Accessions | ENST00000342752.9 [O94772-2] ENST00000631670.1 [O94772-2] ENST00000430474.6 [O94772-1] O94772 ENST00000610554.2 [O94772-1] ENST00000615434.4 [O94772-2] ENST00000615409.1 [O94772-1] ENST00000414417.6 [O94772-2] |